Basic Science Emerging Topic Conference: Inflamed Passions of the Liver: A Journey to Clinical, Translational and Basic Liver Immunology
This engaging two-day conference will explore the latest advancements in understanding the immune landscape of the liver in health and disease. Led by global experts, the program offers a comprehensive look at clinical insights and research of liver immunology.
The conference will feature presentations on a wide range of topics, including:
>> Checkpoint Inhibition and Liver Injury
>> Immune Phenotype of Liver Fibrosis and Cirrhosis
>> Immunologic Features of Autoimmune Liver Diseases
>> Immune Environment in Met-ALD and MASH
>> Role of Immune Cells in Cholangiopathies
>> Tumor Immune Microenvironments in HCC
This ETC is also designed to fuel conversations and discussions for future progress, curated to strengthen networking relationships among attendees.
Note: Attendees must begin registration through the DDW portal. After completing the initial steps, there will be a callout for "Registration Options" and choose AASLD's Basic Science Emerging Topic Conference.
When & Where
Date: Saturday, May 3, 8:00 am - Sunday, May 4, 5:00 pm (EDT) Location: San Diego, CA Program Chairs: Enis Kostallari, MS, PhD | Matthew Burchill, PhD | Bernd Schnabl, MD, FAASLD Continuing Education Credits: Continuing Medical Education (CME): 13.50 AMA PRA Category 1 Credits™
Meet the Program Chairs
View the Program
Saturday, May 3
Keynote Speaker
- Introduction of Dr. MacParland
Enis Kostallari, MS, PhD (Mayo Clinic Rochester) - Spatial Immune Interactions in the Progression of Liver Disease
Sonya MacParland (University Health Network) - Panel Discussion/ Q&A
Session 1: Immune Phenotype of Liver Fibrosis and Cirrhosis
Moderators: Rebecca L. McCullough (University of Colorado-Anschutz) and Bernd Schnabl, MD, FAASLD (University of California, San Diego)
- Immunity and Liver Fibrosis – An Overview
Scott Friedman, MD, FAASLD (Icahn School of Medicine at Mount Sinai (ISMMS)) - Immune Regulation of Liver Fibrosis
Prakash Ramachandran, MBChB PhD BSc(University of Edinburgh) - Pro-inflammatory extracellular signals during fibrosis
Enis Kostallari, MS, PhD (Mayo Clinic Rochester) - Resolvin D1-mediated cellular crosstalk protects against MASH fibrosis
Bishuang Cai, PhD (Icahn School of Medicine at Mount Sinai) - Panel Discussion/ Q&A
Session 2: Role of Immune Cells in Cholangiopathies
Moderators: Cara Mack, MD, FAASLD (Medical College of Wisconsin) and Lily Dara, MD (University of Southern California)
- Clinical Features of Immune-Mediated Cholangiopathies
Alexander Miethke, MD (Cincinnati Children's Hospital) - Beta-catenin Axis in the Immune Response During Cholangiopathies
Kari Nejak-Bowen, MBA, PhD (University of Pittsburgh) - Microbiome Driven Immune Pathology in Cystic Fibrosis-related Liver Disease
Romina Fiorotto, PhD (Yale University) - Panel Discussion/ Q&A
Session 3: New insights into the immune environment of ALD and Met-ALD
Moderators: Xavier Revelo, PhD (University of Minnesota) and Matthias Pinter, PhD (Medical University of Vienna)
- Clinical Features of Immune Mediated Met-ALD
Gyongyi Szabo (Beth Israel Deaconess Medical Center, Harvard Medical School ) - Complement-Mediated Innate Immune Response During ALD
Rebecca L McCullough (University of Colorado - Anschutz) - Adaptive immunity in ALD
Mengfei Liu, MD (Yale University) - Immune Response during ALD
Laura Nagy, PhD, FAASLD (Cleveland Clinic Foundation) - Panel Discussion/ Q&A
Session 4: New Insights into the Immune Environment of MASH
Moderators: Shilpa Grover, MD, MPH (Brigham and Women's Hospital) and Matthew Burchill, PhD (University of Colorado - Anschutz)
- Therapeutic Modulation of the Liver Immune Microenvironment MASH
Anna Mae Diehl, MD, FAASLD (Duke University) - The Emerging Role of B cells in the Pathogenesis of MASH
Xavier Revelo, PhD (University of Minnesota) - Defining Heterogeneity of CD4+ T Cells in MASH
Petra Hirsova, PharmD, PhD (Mayo Clinic Rochester) - Multimodal Profiling of Inflammatory and Immune Cells during MASH
William Alazawi, PhD, FRCP (Blizard Institute) - Panel Discussion/ Q&A
Sunday, May 4
Keynote Speaker
- Introduction of Dr. Flavell
Matthew Burchill, PhD (University of Colorado – Anschutz Medical Campus) - Humanized mouse livers to study immune response in liver diseases
Richard Flavell (Yale University) - Panel Discussion/ Q&A
Session 5: Immunologic Features of Autoimmune Liver Diseases
Moderators: Kari Nejak-Bowen, MBA, PhD (University of Montreal) and Prakash Ramachandran, MBChB PhD BSc(Hons)
- Clinical Features of Adult Autoimmune Hepatitis
David Assis MD (Yale University School of Medicine - Immunobiology of Autoimmune Hepatitis in Children
Cara Mack, MD, FAASLD (Medical College of Wisconsin) - T cell Activation and Clonal Expansion in Autoimmune Hepatitis
Matthew Burchill, PhD (University of Colorado – Anschutz Medical Campus ) - Insights into Novel Candidate Biomarkers for Autoimmune Hepatitis
Claire Harrington, MD (Northwestern Memorial Hospital) - Panel Discussion/ Q&A
Session 6: Navigating the Tumor Immune Microenvironment in Liver Cancer
Moderators: Enis Kostallari, PhD, MS (Mayo Clinic Rochester) and Scott Friedman , MD, FAASLD (Icahn School of Medicine at Mount Sinai)
- Insights from spatial transcriptomics for the treatment of HCC
Luciane T. Kagohara (Johns Hopkins) - MASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC
Mathias Heikenwalder (German Cancer Research Center) - Multimodal Single-Cell Analysis Reveals Immune Landscape Heterogeneity Across Cholangiocarcinoma Subtypes
Sumera Ilyas, MD (Mayo Clinic Rochester) - Immune Landscape of Cholangiocarcinoma
Yury Popov, MD, PhD (BIDMC Harvard Medical School) - Panel Discussion/ Q&A
Session 7: Checkpoint Inhibition Mediated Liver Injury
Moderators: Steve Weinmann MD, PhD, FAASLD (University of Kansas Medical Center)
- Safety and Efficacy of Immunotherapies for HCC
Matthias Pinter, PhD (Medical University of Vienna) - Clinical Pattern of Checkpoint Inhibitor Induced Liver Injury
Shilpa Grover, MBBS, MPH (Brigham and Women's Hospital) - Innate and adaptive immune activation in Immune-mediated Liver Injury from Checkpoint Inhibitors (ILICI)
Lily Dara, MD (University of Southern California) - Panel Discussion/ Q&A
Key Takeaways Include:
>> Cutting-edge knowledge on clinical implications of the immune response during liver disease
>> Translational insights into liver disease treatment, including immune checkpoint inhibitors
>> Comprehensive understanding of the adaptive and innate immune cell biology during liver injury
>> Emerging international research on Met-ALD, MASH, fibrosis and cirrhosis, liver cancer, cholangiopathies, and autoimmune liver disease
>> Meaningful dialogue and idea exchange with take-home new perspectives
>> Supportive atmosphere of young investigators
>> Interactive sessions and possibility to network
Registration Pricing
| Regular Rate | $190 | |
|---|---|---|
| Trainee Rate | $100 |
Continuing Education
Accreditation and Designation Statements
Continuing Medical Education (CME)
Accreditation Statement: The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: AASLD designates this live activity for a maximum of 13.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Claiming CME Credits
CME Credits
Physicians seeking AMA PRA Category 1 CME Credits™ for this live activity must complete the meeting evaluation for DDW 2025. A link to the CME evaluation will be emailed to attendees after the course.